[Skip to Content]
[Skip to Content Landing]
Views 95
Citations 0
Comment & Response
August 2017

Setting the Record Straight on FDA Approvals in Oncology—Reply

Author Affiliations
  • 1Division of General Internal Medicine, University of California-San Francisco, San Francisco
  • 2Department of Medicine, University of California-San Francisco, San Francisco
JAMA Intern Med. 2017;177(8):1223. doi:10.1001/jamainternmed.2017.2254

In Reply We thank Blumenthal and colleagues for their thoughtful comments regarding our Editor’s Note.3 They have correctly identified that the 18 cancer drugs examined in the research letter by Rupp et al1 were not all approved via the accelerated pathway as stated; in fact, many of these cancer drugs were regular approvals. We thank them for pointing out this error and appreciate this opportunity to respond to their other comments.

×